AVCR Stock Overview

Engages in the health data and point-of-care technologies business in Canada. More details

AVCR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Became profitable this year

Risk Analysis

Does not have a meaningful market cap (CA$8M)

Highly volatile share price over the past 3 months compared to the Canadian market

Does not have meaningful revenue (CA$5M)

My Notes

Capture your thoughts, links and company narrative

Avricore Health Inc. Competitors

eChannelling

COSE:ECL.N0000

LK₨1.6b

Vidavo

ATSE:VIDAVO

€2.4m

Media Lab

ENXTPA:MLLAB

€5.3m

Kontigo Care

OM:KONT

SEK 88.4m

Price History & Performance

Summary of share price highs, lows and changes for Avricore Health
Historical stock prices
Current Share Price	CA$0.07
52 Week High	CA$0.34
52 Week Low	CA$0.05
Beta	-2.21
1 Month Change	16.67%
3 Month Change	-66.67%
1 Year Change	-57.58%
3 Year Change	-58.82%
5 Year Change	133.33%
Change since IPO	-99.54%

Recent updates

Shareholder Returns

	AVCR	CA Healthcare Services	CA Market
7D	0%	1.7%	-1.5%
1Y	-57.6%	134.8%	20.4%

Return vs Industry: AVCR underperformed the Canadian Healthcare Services industry which returned 134.8% over the past year.

Return vs Market: AVCR underperformed the Canadian Market which returned 20.4% over the past year.

Price Volatility

Is AVCR's price volatile compared to industry and market?
AVCR volatility
AVCR Average Weekly Movement	21.3%
Healthcare Services Industry Average Movement	9.8%
Market Average Movement	8.2%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: AVCR's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: AVCR's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Hector Bremner	avricore.com

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a turnkey point-of-care testing platform that turns pharmacies into community point-of-care diagnostic centers. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018.

Avricore Health Inc. Fundamentals Summary

How do Avricore Health's earnings and revenue compare to its market cap?
AVCR fundamental statistics
Market cap	CA$8.10m
Earnings (TTM)	CA$103.13k
Revenue (TTM)	CA$4.72m

68.8x

P/E Ratio

1.5x

P/S Ratio

Is AVCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVCR income statement (TTM)
Revenue	CA$4.72m
Cost of Revenue	CA$2.93m
Gross Profit	CA$1.79m
Other Expenses	CA$1.69m
Earnings	CA$103.13k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.001
Gross Margin	37.97%
Net Profit Margin	2.19%
Debt/Equity Ratio	0%

How did AVCR perform over the long term?

See historical performance and comparison

AVCR Stock Overview

Rewards

Risk Analysis

Avricore Health Inc. Competitors

COSE:ECL.N0000

LK₨1.6b

ATSE:VIDAVO

€2.4m

ENXTPA:MLLAB

€5.3m

OM:KONT

SEK 88.4m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.003 loss in 3Q 2023)

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

CTO & Director recently sold CA$51k worth of stock

Recent updates

Third quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.003 loss in 3Q 2023)

New major risk - Share price stability

New major risk - Market cap size

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.003 loss in 2Q 2023)

CTO & Director recently sold CA$51k worth of stock

First quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.002 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in FY 2022)

Avricore Health Inc., Annual General Meeting, Jun 20, 2024

New major risk - Market cap size

New minor risk - Share price stability

Insufficient new directors

Third quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 3Q 2022)

Avricore Health Inc. Expands Its Innovative Point-Of-Care Chronic and Infectious Disease Screening and Health- Data Management Platform, Healthtab

New minor risk - Share price stability

Avricore Health Inc. Announces Board Changes

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 1Q 2022)

Avricore Health Inc., Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: CA$0.008 loss per share (vs CA$0.018 loss in FY 2021)

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.009 loss in 1Q 2021)

Avricore Health Inc., Annual General Meeting, Jul 21, 2022

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

High number of new and inexperienced directors

Full year 2021 earnings released: CA$0.018 loss per share (vs CA$0.019 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Avricore Health Inc Begins Patient Testing on the HealthTab™ Platform in Select Shoppers Drug Mart® Pharmacies

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

Avricore Health Inc. Patient Testing Has Begun on the First Deployment of the New HealthTab

Independent Director exercised options to buy CA$80k worth of stock.

Avricore Health Inc. Begins Patient Testing on First Deployment of New HealthTabTM-Integrated Afinion 2TM Analyzers in Initial Shoppers Drug Mart® Pharmacy Location

Avricore Health Inc. Signs Master Agreement to Pilot Healthtab Platform for Diabetes Management in Select Shoppers Drug Mart Pharmacies

Avricore Health Inc. Successfully Launches HealthTab™ in the First of 11 Shoppers Drug Mart Pilot Locations

Avricore Health's HealthTab Achieves Critical Milestones in Connecting New Testing Device

First quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.041 loss in FY 2019)

Avricore Health Inc. Signs Letter of Intent with Avrok Laboratories

Avricore Health Inc. announced that it has received CAD 1.54 million in funding

Whole Health Pharmacy Partners to Launch Avricore’s Healthtab™

Avricore Health Inc. announced that it expects to receive CAD 1.54 million in funding

New 90-day high: CA$0.27

Avricore Health Inc. Announces Board Changes

Avricore Health Inc. announced that it has received CAD 1.5 million in funding

New 90-day high: CA$0.26

Avricore Health Inc. Successfully Intergrates ID Now™ Rapid PCR Test Device, Offering Real-Time Covid-19 Reporting Direct from Instrument for First Time

Avricore Health Announces Management Changes

Third quarter 2020 earnings released: CA$0.003 loss per share

Avricore Health Inc. announced that it expects to receive CAD 1.5 million in funding

Healthtab Integrating New Device to Add Hba1c Blood Glucose Testing to Its Real-Time Data Reporting System

Shareholder Returns

Price Volatility

About the Company

Avricore Health Inc. Fundamentals Summary

68.8x

1.5x

Earnings & Revenue